Detalhe da pesquisa
1.
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
Blood
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38484137
2.
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
Blood
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38684038
3.
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Blood
; 140(25): 2697-2708, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35700381
4.
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
Blood
; 140(19): 2024-2036, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35914220
5.
The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.
Haematologica
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813715
6.
Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort.
BMC Cancer
; 24(1): 584, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38741031
7.
Functional genomic landscape of acute myeloid leukaemia.
Nature
; 562(7728): 526-531, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30333627
8.
CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma.
Mol Cancer
; 22(1): 64, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36998071
9.
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Blood
; 137(3): 374-386, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32663292
10.
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment.
Oncologist
; 27(1): 57-66, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35305092
11.
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.
Curr Opin Oncol
; 34(5): 540-545, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35855508
12.
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.
Br J Clin Pharmacol
; 88(2): 836-841, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196037
13.
Migraine and light: A narrative review.
Headache
; 62(1): 4-10, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041220
14.
CAR T-Cell Therapy in the Older Person: Indications and Risks.
Curr Oncol Rep
; 24(9): 1189-1199, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35420395
15.
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Br J Haematol
; 193(1): 15-25, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216986
16.
Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
Br J Haematol
; 192(4): 720-728, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32599655
17.
Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
Blood
; 134(19): 1573-1577, 2019 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31554637
18.
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Invest New Drugs
; 39(4): 1099-1105, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33683501
19.
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
Haematologica
; 106(11): 2845-2852, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054118
20.
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Haematologica
; 106(7): 1932-1942, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538152